HIV Treatment

Drug Resistance

Key Points

  • HIV mutations sometimes develop while a person is taking HIV medicines, which may cause drug-resistant HIV that can be transmitted to other people.
  • Once drug resistance develops, HIV medicines that previously controlled a person’s HIV are no longer effective. In other words, the HIV medicines cannot prevent the drug-resistant HIV from multiplying, causing the treatment to fail.
  • By identifying which, if any, HIV medicines will not be effective against HIV, drug resistance testing can help determine which HIV medicines to include in an HIV treatment regimen.
  • Taking HIV medicines exactly as prescribed reduces the risk of drug resistance.

 

What is HIV drug resistance?

As HIV multiplies in the body, it sometimes changes form, known as a mutation. Some HIV mutations can cause resistance to HIV medicines (called HIV drug resistance), which means that the virus will be resistant to all or some parts of a prescribed HIV medicine.

In some cases, HIV drug resistance can reduce the effectiveness of multiple drugs in a class of HIV medicines. For example, resistance to the nucleoside reverse transcriptase inhibitor (NRTI) emtricitabine can cause resistance to lamivudine or other NRTIs.

Drug resistance can develop over time in people with HIV or can be spread from person to person (called transmitted resistance), which includes perinatal transmission during pregnancy. This means that some people will have drug-resistant HIV even before they take HIV medicines.

For people who develop HIV drug resistance while taking HIV medicines, the original treatment regimen is unlikely to continue being effective. In other words, the original HIV medicines cannot prevent the drug-resistant HIV from multiplying, and the HIV treatment will fail unless a different treatment regimen is started.

On the other hand, people who acquire transmitted HIV resistance may not respond to certain treatment regimens, even if it is their first time taking HIV medicines. To prevent HIV from multiplying due to an ineffective treatment regimen, it is important to receive drug resistance testing as soon as possible after receiving an HIV diagnosis.

What is drug-resistance testing?

Drug-resistance testing identifies which, if any, HIV medicines will not be effective for a person with HIV. Drug-resistance testing evaluates resistance to common drug classes (such as protease inhibitors) using a sample of blood.

People with HIV should start taking HIV medicines as soon as possible after an HIV diagnosis. However, drug-resistance testing is usually performed before a person starts taking HIV medicines. Drug-resistance test results help determine which HIV medicines to include in a person’s first HIV treatment regimen.

Once HIV treatment is started, a viral load test is used to monitor whether the HIV medicines are working effectively. If viral load testing indicates that a person’s HIV treatment regimen is not effective, drug-resistance testing is repeated. The test results can identify whether drug resistance is the problem and, if so, can be used to select a new HIV treatment regimen.

How can a person taking HIV medicines reduce the risk of drug resistance?

Taking HIV medicines exactly as prescribed (called medication adherence) reduces the risk of drug resistance. Even occasionally skipping HIV medicines can allow HIV to multiply, which increases the risk that the virus will mutate and produce drug-resistant HIV.

Before starting HIV treatment, people with HIV should tell their health care provider about any issues that can make medication adherence difficult. For example, a busy schedule or lack of health insurance can make it hard to take HIV medicines consistently. Read the HIVinfo fact sheet HIV Treatment Adherence for a list of other common causes of poor medication adherence.

Health care providers can help find a suitable treatment regimen that increases the likelihood of medication adherence and reduces the risk of drug resistance.

For people who are actively engaging in sexual activity, the risk of transmitted drug resistance can be significantly reduced if their partner(s) take pre-exposure prophylaxis (PrEP). PrEP nearly eliminates the risk of sexual HIV transmission for partners, including the transmission of drug-resistant HIV. PrEP offers protection in the event of unnoticed or unexpected drug resistance.

The following HIVinfo resources offer more information on drug resistance and medication adherence:


This fact sheet is based on information from the following sources:

From the HIV Clinical Practice Guidelines at Clinicalinfo.HIV.gov:

From the Department of Veterans Affairs:

From the National Institute of Allergy and Infectious Diseases:

Also see the HIV Source collection of HIV links and resources.

FDA-Approved HIV Medicines

Treatment with HIV medicines is called antiretroviral therapy (ART). ART is recommended for everyone with HIV, and people with HIV should start ART as soon as possible. People on ART take a combination of HIV medicines (called an HIV treatment regimen) every day or by schedule (injections).

A person's initial HIV treatment regimen generally includes three HIV medicines from at least two different HIV drug classes. In many cases, different oral medicines may be combined into a single pill or capsule. Some people are eligible to receive newer long-acting medicines in the form of injections every one or two months.

The following table lists HIV medicines recommended for the treatment of HIV infection in the United States, based on the HIV Clinical Practice Guidelines at Clinicalinfo.HIV.gov.

These drugs have been approved by the U.S. Food and Drug Administration (FDA). Some drugs were approved by the FDA but later discontinued, either as brand-name and/or generic versions. Discontinued drugs are listed in the table below for historical reference.

The HIV medicines are listed according to drug class and identified by generic and brand names. Click on a drug name to view information on the drug from the Clinicalinfo Drug Database.

To see a timeline of all FDA approval dates for HIV medicines, view the HIVinfo FDA Approval of HIV Medicines infographic. To learn more about how each drug class prevents HIV from spreading in the body, view the HIV Life Cycle fact sheet.


*Although some brand-name HIV medicines have been discontinued, generic versions of the same drug formulation remain available.

FDA Approved HIV Medicines – Nucleoside Reverse Transcriptase Inhibitors (NRTIs)

NRTIs block reverse transcriptase, an enzyme HIV needs to make copies of itself.

Generic Name
(Other names and acronyms)

Brand Name

FDA Approval Date

abacavir 
(abacavir sulfate, ABC)
ZiagenDecember 17, 1998
emtricitabine
(FTC)
EmtrivaJuly 2, 2003
lamivudine 
(3TC)
EpivirNovember 17, 1995
tenofovir disoproxil 
fumarate
(tenofovir DF, TDF)
VireadOctober 26, 2001
tenofovir alafenamide
(tenofovir AF, TAF)
VemlidyNovember 10, 2016
zidovudine
(azidothymidine, AZT, ZDV)
RetrovirMarch 19, 1987

FDA Approved HIV Medicines – Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

NNRTIs block reverse transcriptase, an enzyme HIV needs to make copies of itself.

Generic Name
(Other names and acronyms)

Brand Name

FDA Approval Date

doravirine 
(DOR)
PifeltroAugust 30, 2018
efavirenz 
(EFV)
Sustiva
(discontinued)*
September 17, 1998
etravirine 
(ETR)
IntelenceJanuary 18, 2008
nevirapine 
(NVP)
Viramune
(discontinued)*
June 21, 1996
Viramune XR (extended-release)
(discontinued)*
March 25, 2011
rilpivirine
(rilpivirine hydrochloride, RPV)
EdurantMay 20, 2011
Edurant PED
(discontinued)
March 15, 2024

FDA Approved HIV Medicines – Integrase Strand Transfer Inhibitors (INSTIs)

INSTIs block HIV integrase, an enzyme HIV needs to make copies of itself.

Generic Name
(Other names and acronyms)

Brand Name

FDA Approval Date

cabotegravir
(cabotegravir sodium, CAB)
Apretude (injection)December 20, 2021
Vocabria (tablet)January 22, 2021
dolutegravir
(dolutegravir sodium, DTG)
TivicayAugust 12, 2013
Tivicay PDJune 12, 2020
raltegravir
(raltegravir potassium, RAL)
IsentressOctober 12, 2007
Isentress HDMay 26, 2017

FDA Approved HIV Medicines – Protease Inhibitors (PIs)

PIs block HIV protease, an enzyme HIV needs to make copies of itself.

Generic Name
(Other names and acronyms)

Brand Name

FDA Approval Date

atazanavir
(atazanavir sulfate, ATV)
ReyatazJune 20, 2003
darunavir
(darunavir ethanolate, DRV)
PrezistaJune 23, 2006
fosamprenavir
(fosamprenavir calcium, FOS-APV, FPV)
Lexiva
(discontinued)*
October 20, 2003
ritonavir
(RTV)
NorvirMarch 1, 1996
tipranavir
(TPV)
AptivusJune 22, 2005

Note: Although ritonavir is a PI, it is generally used as a pharmacokinetic enhancer as recommended in the Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV and the Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection.


FDA Approved HIV Medicines – Fusion Inhibitors

Fusion inhibitors block HIV from entering the CD4 T lymphocytes (CD4 cells) of the immune system.

Generic Name
(Other names and acronyms)

Brand Name

FDA Approval Date

enfuvirtide
(T-20)
Fuzeon
(discontinued)
March 13, 2003

FDA Approved HIV Medicines – CCR5 Antagonists

CCR5 antagonists block CCR5 coreceptors on the surface of certain immune cells that HIV needs to enter the cells.

Generic Name
(Other names and acronyms)

Brand Name

FDA Approval Date

maraviroc
(MVC)
SelzentryAugust 6, 2007

FDA Approved HIV Medicines – Attachment Inhibitors

Attachment inhibitors bind to the gp120 protein on the outer surface of HIV, preventing HIV from entering CD4 cells.

Generic Name
(Other names and acronyms)

Brand Name

FDA Approval Date

fostemsavir
(fostemsavir tromethamine, FTR)
RukobiaJuly 2, 2020

FDA Approved HIV Medicines – Post-Attachment Inhibitors

Post-attachment inhibitors block CD4 receptors on the surface of certain immune cells that HIV needs to enter the cells.

Generic Name
(Other names and acronyms)

Brand Name

FDA Approval Date

ibalizumab-uiyk
(IBA, Hu5A8, TMB-355, TNX-355)
TrogarzoMarch 6, 2018

FDA Approved HIV Medicines – Capsid Inhibitors

Capsid inhibitors interfere with the HIV capsid, a protein shell that protects HIV's genetic material and enzymes needed for replication.

Generic Name
(Other names and acronyms)

Brand Name

FDA Approval Date

lenacapavir
(LEN, GS-6207, GS-HIV, GS-CA2, GS-CA1)
SunlencaDecember 22, 2022

FDA Approved HIV Medicines – Pharmacokinetic Enhancers

Pharmacokinetic enhancers are used in HIV treatment to increase the effectiveness of an HIV medicine included in an HIV treatment regimen.

Generic Name
(Other names and acronyms)

Brand Name

FDA Approval Date

cobicistat 
(COBI, c)
TybostSeptember 24, 2014

FDA Approved HIV Medicines – Combination HIV Medicines

Combination HIV medicines contain two or more HIV medicines from one or more drug classes.

Generic Name
(Other names and acronyms)

Brand Name

FDA Approval Date

abacavir and lamivudine 
(abacavir sulfate / lamivudine, ABC / 3TC)
Epzicom
(discontinued)*
August 2, 2004
abacavir, dolutegravir, and lamivudine (abacavir sulfate / dolutegravir sodium / lamivudine, ABC / DTG / 3TC)TriumeqAugust 22, 2014
Triumeq PDMarch 30, 2022
abacavir, lamivudine, and zidovudine
(abacavir sulfate / lamivudine / zidovudine, ABC / 3TC / ZDV)
Trizivir
(discontinued)*
November 14, 2000
atazanavir and cobicistat
(atazanavir sulfate / cobicistat, ATV / COBI)
EvotazJanuary 29, 2015
bictegravir, emtricitabine, and tenofovir alafenamide 
(bictegravir sodium / emtricitabine / tenofovir AF, BIC / FTC / TAF)
BiktarvyFebruary 7, 2018
cabotegravir and rilpivirine
(cabotegravir / rilpivirine, CAB / RPV, CAB plus RPV, Cabenuva kit, cabotegravir extended-release injectable suspension and rilpivirine extended-release injectable suspension)
CabenuvaJanuary 22, 2021
darunavir and cobicistat
(darunavir ethanolate / cobicistat, DRV / COBI)
PrezcobixJanuary 29, 2015
darunavir, cobicistat, emtricitabine, and tenofovir alafenamide
(darunavir ethanolate / cobicistat / emtricitabine / tenofovir AF, DRV / COBI / FTC / TAF)
SymtuzaJuly 17, 2018
dolutegravir and lamivudine
(dolutegravir sodium / lamivudine, DTG / 3TC)
DovatoApril 8, 2019
dolutegravir and rilpivirine
(dolutegravir sodium / rilpivirine hydrochloride, DTG / RPV)
JulucaNovember 21, 2017
doravirine, lamivudine, and tenofovir disoproxil fumarate
(doravirine / lamivudine / tenofovir DF, DOR / 3TC / TDF)
DelstrigoAugust 30, 2018
efavirenz, emtricitabine, and tenofovir disoproxil fumarate
(efavirenz / emtricitabine / tenofovir DF, EFV / FTC / TDF)
Atripla
(discontinued)*
July 12, 2006
efavirenz, lamivudine, and tenofovir disoproxil fumarate
(efavirenz / lamivudine / tenofovir DF, EFV / 3TC / TDF)
SymfiMarch 22, 2018
Symfi Lo
(discontinued)*
February 5, 2018
elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide
(elvitegravir / cobicistat / emtricitabine / tenofovir AF, EVG / COBI / FTC / TAF)
GenvoyaNovember 5, 2015
elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate
(elvitegravir / cobicistat / emtricitabine / tenofovir DF, EVG / COBI / FTC / TDF)
StribildAugust 27, 2012
emtricitabine, rilpivirine, and tenofovir alafenamide
(emtricitabine / rilpivirine hydrochloride / tenofovir AF, FTC / RPV / TAF)
OdefseyMarch 1, 2016
emtricitabine, rilpivirine, and tenofovir disoproxil fumarate
(emtricitabine / rilpivirine hydrochloride / tenofovir DF, FTC / RPV / TDF)
CompleraAugust 10, 2011
emtricitabine and tenofovir alafenamide
(emtricitabine / tenofovir AF, FTC / TAF)
DescovyApril 4, 2016
emtricitabine and tenofovir disoproxil fumarate
(emtricitabine / tenofovir DF, FTC / TDF)
TruvadaAugust 2, 2004
lamivudine and tenofovir disoproxil fumarate
(lamivudine / tenofovir DF, 3TC / TDF)
CimduoFebruary 28, 2018
lamivudine and zidovudine
(lamivudine / zidovudine, 3TC / ZDV)
Combivir
(discontinued)*
September 27, 1997
lopinavir and ritonavir
(ritonavir-boosted lopinavir, LPV / r, LPV / RTV)
KaletraSeptember 15, 2000

This fact sheet is based on information from the following sources:

From FDA:

From the National Library of Medicine:

Also see the HIV Source collection of HIV links and resources.

Following an HIV Treatment Regimen: Steps to Take Before and After Starting HIV Medicines

Key Points

  • Medication adherence is essential to make sure HIV treatment is as effective as possible.
  • Before starting an HIV treatment regimen, tell your health care provider if there are any reasons that could make it hard for you to follow a treatment regimen. Some examples include difficulty swallowing pills, financial difficulties, unstable housing, or a busy schedule.
  • After starting an HIV treatment regimen, medication aids such as pill boxes, apps, and medication diaries can help to maintain long-term medication adherence.

 

Benefits of HIV treatment adherence

What should you do before starting an HIV treatment regimen?

Talking with your health care provider will help you understand why you are starting HIV treatment and why medication adherence is important. Medication adherence means sticking to an HIV treatment regimen—taking HIV medicines as scheduled and exactly as prescribed.

Treatment with HIV medicines (called antiretroviral therapy or ART) is recommended for everyone with HIV. When taken as prescribed, HIV medicines help people with HIV live long, healthy lives. Adherence to an HIV treatment regimen also reduces the risk of drug resistance and HIV transmission.

What should you tell your health care provider before starting an HIV treatment regimen?

Tell your health care provider about other prescription and nonprescription medicines, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Other medicines or products you take may interact with HIV medicines, causing a drug interaction. A drug interaction may affect how an HIV medicine works or cause side effects. To learn more, read the HIVinfo What is a Drug Interaction? fact sheet.

Tell your health care provider about any issues that might make adherence difficult. For example, people who have difficulty swallowing pills or people who do not have health insurance may find it hard to stick to an HIV treatment regimen. Other issues could include a busy schedule, lack of transportation, lack of stable housing, HIV medicine side effects, substance use, and fear of judgment. To learn more, read the HIVinfo HIV Treatment Adherence fact sheet.   

Describe your daily schedule to your health care provider. You and your health care provider can work together to design an HIV medication schedule that fits in with your day-to-day routine.

Ask your health care provider for written instructions on how to follow your HIV treatment regimen. The instructions should include information about how, when, and how much of the medicine you should take.

What are the best ways to stick to an HIV treatment regimen?

To maintain adherence, try some of the following strategies:

  • Use a 7-day pill box. Once a week, fill the pill box with your HIV medicines for the entire week.
  • Take your HIV medicines at the same time every day.
  • Set an alarm on your cell phone to remind you to take your medicines.
  • Ask a family member or friend to remind you to take your medicines.
  • Plan and prepare for changes in your daily routine, including weekends and holidays. If you are going away, pack enough medicine to last the entire trip.
  • Use an app or a medicine diary (online or on paper) to record each medicine as you take it. Reviewing your diary will help you identify the times that you are most likely to forget to take your medicines.
  • Keep all of your medical appointments. Be sure to refill your prescriptions before you run out of HIV medicines.

What should you do if you forget to take your HIV medicines?

Unless your health care provider tells you otherwise, take the medicine you missed as soon as you realize you missed a normal dose, unless it is almost time for the next dose. Do not take a double dose of an HIV medicine to make up for a missed dose.

Tell your health care provider if you are having difficulty following your treatment regimen. Do not forget to mention any side effects you are having. Side effects from HIV medicines (or from other medicines that you are taking) can interfere with medication adherence for any reason.


This fact sheet is based on information from the following sources:

From the NIH Office of AIDS Research:

From the Health Resources and Services Administration:

From HIV.gov:

From the U.S. Department of Veterans Affairs:

Also see the HIV Source collection of HIV links and resources.

HIV and Immunizations

Key Points

  • Although there are no vaccines to prevent or treat HIV, people with HIV can benefit from getting vaccines against other diseases like hepatitis B and influenza.
  • Factors such as age, previous vaccinations, likelihood of getting a particular disease, certain HIV-related factors, and pregnancy status can impact which vaccines are recommended.

 

What are vaccines?

Vaccines protect people from diseases, such as the primary varicella infection (chickenpox), influenza (flu), and polio. Vaccines are given by needle injection (a shot), by mouth (pill or solution), or by nasal spray. The process of getting a vaccine is called vaccination or immunization.

When a person gets a vaccine, the body's immune system mounts an immune response that protects the body against the disease. In this way, the immune system learns to defend the body if the person is later exposed to the disease. 

Some vaccines, like the measles or polio vaccines, are nearly 100% effective at preventing disease. Others, like the COVID-19 or flu vaccines, reduce the severity of the disease so that only a mild case of the disease occurs.

Vaccines not only protect individuals from disease; they protect communities as well. When most people in a community get immunized against a disease, there is little chance of a disease outbreak.

Is there a vaccine against HIV?

Researchers have been studying HIV vaccines for nearly 40 years. Most of the HIV vaccine trials have been early-stage trials where scientists look at whether the vaccine is safe and whether we mount an immune response to HIV following vaccination.

Very few vaccine trials have advanced to late-stage testing where scientists look at whether the vaccine effectively stops HIV infection. So far, no HIV vaccines have proven effective, and none have been approved for use outside of clinical trials.

Even with recent setbacks, scientists are looking at new technologies to design experimental vaccines to prevent and treat HIV. For more information about experimental HIV vaccines, read the HIVinfo fact sheets What is a Preventive HIV Vaccine? and What is a Therapeutic HIV Vaccine?

Even though there are no vaccines to prevent or treat HIV, people with HIV can benefit from vaccines against other diseases.

Which vaccines are recommended for people with HIV?

People with HIV should speak with their health care provider about receiving:

  • COVID-19 vaccine annually
  • Hepatitis A vaccine series
  • Hepatitis B vaccine series
  • HPV vaccine series to protect against human papillomavirus (for those up to age 26 years)
  • Influenza vaccine annually to protect against seasonal flu
  • Meningococcal conjugate vaccine series
  • Pneumococcal vaccine(s)
  • Respiratory syncytial virus vaccine series (for those who are at least age 75 years)
  • Tdap/Td vaccines to protect against tetanus, diphtheria, and pertussis (whooping cough)
  • Zoster vaccine series to protect against shingles

People with HIV are more likely to get many of these diseases than people who don’t have HIV, so they should talk with their health care providers to determine which vaccines they should receive and when they should receive them.

Other factors, such as age, previous vaccinations, likelihood of getting a particular disease, CD4 T lymphocyte (CD4 cell) count, and pregnancy status, can impact which vaccines are recommended. For example, if you are age 60 and have a low CD4 cell count, your health care provider may recommend that you receive the RSV vaccine series.

Similarly, if you know you have been exposed to mpox or engage in sexual behaviors that increase your chance of getting mpox, your health care provider may suggest that you get vaccinated against mpox.

Are vaccines safe for people with HIV?

Most vaccines are safe and effective for people with HIV. Although some people may experience side effects from vaccines, these are generally minor and go away in a few days. For example, some people experience soreness at the location of an injection or a mild fever that resolve after a few days. Severe reactions to vaccines are rare.

Some vaccines, such as the live attenuated versions of the flu vaccine and mpox vaccine, are not recommended for people with HIV because they can potentially cause an infection in people with HIV. However, alternative vaccines to protect against flu and mpox are available.

Before getting a vaccine, talk to your health care provider about the benefits of the vaccine and possible side effects.

What about travel and immunizations?

Regardless of destination, all travelers should be up to date on routine vaccinations. However, people who plan to travel outside the United States may need to be vaccinated against diseases that are present in other parts of the world:

  • Cholera: Africa, the Americas, South and Southeast Asia
  • Polio: Afghanistan, Pakistan
  • Typhoid: Africa, Asia (especially South Asia), Latin America
  • Yellow Fever: sub-Saharan Africa, tropical South America

If you have HIV, talk to your health care provider about any vaccines you may need before you travel outside of the United States.

To prepare for your trip, read information from the Centers for Disease Control and Prevention (CDC) on Travelers with Weakened Immune Systems.


This fact sheet is based on information from the following sources:

From CDC:

From the Department of Health and Human Services:

From HIV Clinical Practice Guidelines at Clinicalinfo.HIV.gov:

Also see the HIV Source collection of HIV links and resources.

HIV Treatment Adherence

Key Points

  • Treatment adherence includes starting HIV treatment, keeping all medical appointments, and taking HIV medicines exactly as prescribed. For people with HIV, treatment adherence is key to staying healthy.
  • After confirming an HIV diagnosis, people with HIV should see a health care provider to start taking HIV medicines as soon as possible.
  • Because HIV requires lifelong treatment, people with HIV should regularly visit their health care provider. Ongoing medical care includes monitoring to make sure a person's HIV treatment regimen is keeping the virus under control.

 

What is HIV treatment adherence?

For people with HIV, treatment adherence means:

  • Starting HIV treatment
  • Taking HIV medicines exactly as prescribed (also called medication adherence)
  • Keeping all medical appointments

Adherence to treatment is a key part of staying healthy with HIV.

How soon should a person start treatment after testing positive for HIV?

Once someone gets diagnosed with HIV, it is best to see a health care provider as soon as possible to discuss HIV medicines and find the best treatment regimen for their specific needs. Treatment with HIV medicines (called antiretroviral therapy or ART) is recommended for everyone with HIV and can help them live long, healthy lives. HIV medicines also reduce the risk of HIV transmission.

Because HIV requires lifelong treatment, it is important for people with HIV to regularly visit their health care provider. Health care providers periodically monitor people with HIV to make sure their treatment regimen is working effectively.

During regular medical appointments, health care providers can also recommend resources to help people deal with any issues that may interfere with medication adherence.

Why is medication adherence important?

Taking HIV medicines as they are prescribed prevents HIV from multiplying, which reduces the risk that HIV will mutate and produce drug-resistant HIV. Skipping HIV medicines allows HIV to multiply, which increases the risk of HIV drug resistancetreatment failure, and transmission to others.

Poor adherence to an HIV treatment regimen also allows HIV to destroy the immune system. A damaged immune system makes it hard for the body to fight off infections and certain cancers.

What are common causes of poor medication adherence?

Maintaining good medication adherence can be difficult for many reasons. The table below provides examples of barriers to medication adherence, with some potential solutions to help overcome those barriers.

Adherence Barrier

Potential Solution

Busy scheduleTreatment planner (or pill organizer)
Lack of health insuranceRyan White HIV/AIDS Program (RWHAP) services; AIDS Drug Assistance Programs (ADAPs)
Lack of transportation“Meds to Beds” programs; prescription delivery
Lack of stable housingHousing resources from the US Department of Housing and Urban Development
Trouble swallowing pillsSingle-tablet regimens; injectable HIV medicines
HIV medicine side effectsConsult with your health care provider for a new HIV treatment regimen
Substance useMultidisciplinary support; directly-observed therapy; Substance Abuse and Mental Health Services Administration (SAMHSA) resources
Fear of judgmentScreening and counseling for unmet social needs; stigma education

Any barriers from the table above can make it hard to take HIV medicines consistently. A health care provider can help find a suitable treatment regimen that increases the likelihood of medication adherence.

Where can a person find resources to help with HIV treatment adherence?

Explore these HIVinfo and Centers for Disease Control and Prevention (CDC) resources to learn more about treatment adherence:

HIVinfo:

CDC:


This fact sheet is based on information from the following sources:

From the NIH Office of AIDS Research:

From the Health Resources and Services Administration:

From HIV.gov:

Also see the HIV Source collection of HIV links and resources.

HIV Treatment: The Basics

Key Points

  • The treatment for HIV is called antiretroviral therapy (ART). ART involves taking a combination of HIV medicines daily, monthly, or every other month.
  • While ART cannot cure HIV, prompt HIV treatment can help all people with HIV live long, healthy lives and reduce the risk of HIV transmission.
  • One of the primary goals of HIV treatment is to reduce a person’s viral load to an undetectable level, which nearly eliminates the risk of transmitting HIV through sexual contact.

 

What is the treatment for HIV?

The treatment for HIV is called antiretroviral therapy (ART). ART involves taking a combination of HIV medicines (called an HIV treatment regimen) on a regular schedule, usually every day (pills) or once a month/every two months (injections).

ART is recommended for everyone who has HIV. ART cannot cure HIV, but these HIV medicines help people with HIV live long, healthy lives. ART also reduces the risk of HIV transmission.

How do HIV medicines work?

HIV attacks and destroys the infection-fighting CD4 T lymphocytes (CD4 cells) of the immune system. Loss of CD4 cells makes it hard for the body to fight off infections, including opportunistic infections and some HIV-related cancers.

HIV medicines prevent HIV from multiplying (making copies of itself), which reduces the amount of HIV in the body (called the viral load). Having less HIV in the body gives the immune system a chance to recover and produce more infection-fighting CD4 cells. Although there may still be HIV in the body, the additional CD4 cells keep the immune system strong enough to fight off infections.

By reducing the amount of HIV in the body, HIV medicines also reduce the risk of HIV transmission. One of the main goals of HIV treatment is to reduce a person’s viral load to an undetectable level. People with HIV who maintain an undetectable viral load have effectively no risk of transmitting HIV through sex, and a significantly lower risk of transmission through other means (such as shared needles).

When is it time to start taking HIV medicines? 

People with HIV should start taking HIV medicines as soon as possible after an HIV diagnosis. It is especially important for people with AIDS-defining conditions or within 6 months of HIV infection (called early HIV infection) to start HIV medicines right away.

Women with HIV who become pregnant and are not already taking HIV medicines should also start taking HIV medicines as soon as possible. It is important for people with HIV to take their HIV medicines as prescribed, which could be every day (pills) or every one or two months (injections).

What HIV medicines are included in an HIV treatment regimen?

There are many FDA-approved HIV medicines available for HIV treatment regimens. The HIV medicines are grouped into seven drug classes according to how they fight HIV.

The choice of an HIV treatment regimen depends on a person's individual needs. When choosing an HIV treatment regimen, people with HIV and their health care providers consider many factors, including possible side effects of HIV medicines and potential drug interactions.

What should people know about taking HIV medicines?

Taking HIV medicines keeps people with HIV healthy and prevents HIV transmission. Taking HIV medicines exactly as prescribed (called medication adherence) also reduces the risk of drug resistance.

However, sometimes HIV medicines can cause side effects. Most side effects from HIV medicines are manageable, but a few can be serious. Overall, the benefits of HIV medicines far outweigh the risk of side effects.

In some cases, HIV medicines can interact with other medicines in an HIV treatment regimen or with other medicines a person is taking. Health care providers carefully consider potential drug interactions before recommending an HIV treatment regimen.

If you believe you are experiencing side effects from HIV medicines, it is important to consult with your health care provider before stopping or adjusting your normal treatment regimen.

Where can a person learn more about HIV treatment?

Read the other fact sheets in the HIVinfo HIV Treatment series to learn more about HIV treatment. Topics covered in this series include:


This fact sheet is based on information from the following sources:

From the NIH Office of AIDS Research:

From the Centers for Disease Control and Prevention:

From the Department of Veterans Affairs:

From the National Institute of Allergy and Infectious Diseases:

Also see the HIV Source collection of HIV links and resources.

Just Diagnosed: Next Steps After Testing Positive for HIV

Key Points

  • Although an HIV diagnosis might seem overwhelming, it is important to remember that HIV can be treated effectively with HIV medicines, allowing people with HIV to live long, healthy lives.
  • The first step after testing positive for HIV is to see a health care provider, even if you do not feel sick. Prompt medical care and treatment with HIV medicines as soon as possible is the best way to stay healthy.
  • After testing positive for HIV, a person’s first visit with a health care provider includes a review of the person’s health and medical history, a physical exam, and several lab tests.

 

What is the next step after testing positive for HIV?

Testing positive for HIV often leaves a person overwhelmed with questions and concerns. It is important to remember that HIV can be treated effectively with HIV medicines.

Treatment with HIV medicines (called antiretroviral therapy or ART) is recommended for everyone with HIV. HIV medicines help people with HIV live long, healthy lives and reduce the risk of HIV transmission.

After testing positive for HIV, it is important to see a health care provider as soon as possible, even if you do not feel sick. Prompt medical care and treatment with HIV medicines is the best way to stay healthy.

After testing positive for HIV, what can a person expect during their first visit with a health care provider?

A person’s first visit with a health care provider after testing positive for HIV includes a review of the person’s health and medical history, a physical exam, and several lab tests. The information collected during this visit is used to make decisions about HIV treatment.

During this session, the health care provider also explains the benefits of HIV treatment and discusses ways to reduce the risk of passing HIV to others.

Which lab tests are used to make decisions about HIV treatment?

A health care provider reviews a person’s lab test results to determine how far the person’s HIV infection has advanced (called HIV progression) and to decide which HIV medicines to recommend.

The following lab tests are used to make decisions about HIV treatment.

CD4 count
A CD4 count measures the number of CD4 cells in a sample of blood. CD4 cells are infection-fighting cells of the immune system. As HIV advances, a person’s CD4 count drops, which indicates increasing damage to the immune system. Treatment with HIV medicines prevents HIV from destroying CD4 cells. 

Viral load
viral load test measures how much virus is in the blood (HIV viral load). As HIV progresses to acquired immunodeficiency syndrome (AIDS) (if untreated), a person’s viral load increases. HIV medicines prevent HIV from multiplying, which reduces a person’s viral load. A goal of HIV treatment is to keep a person’s viral load so low that the virus cannot be detected by a viral load test. This is known as having an undetectable viral load.

Once HIV treatment is started, the CD4 count and viral load are used to monitor whether the HIV medicines are controlling a person’s HIV.

Drug-resistance testing
Health care providers consider many factors when recommending HIV medicines, including a person’s drug-resistance test results. Drug-resistance testing identifies which, if any, HIV medicines will not be effective against a person’s strain of HIV.

The HIVinfo infographic What do my lab results mean? has more information about tests used to monitor HIV infection and treatment.

After testing positive for HIV, how soon do people start taking HIV medicines?

People with HIV should start taking HIV medicines as soon as possible after receiving an HIV diagnosis. However, before starting treatment, health care providers and people with HIV should discuss available HIV medicines.

Issues, such as lack of health insurance or an inability to pay for certain HIV medicines, can make it hard to take HIV medicines consistently. Health care providers can recommend resources to help people deal with any issues related to HIV treatment adherence before starting an HIV treatment regimen.

During a person’s first visit with a health care provider, is there time to ask questions?

Yes, an initial visit with a health care provider is a good time to ask questions. The following are some questions that people with newly diagnosed HIV typically ask:

  • Because I have HIV, will I eventually get AIDS?
  • What can I do to stay healthy and avoid getting other infections?
  • How can I prevent passing HIV to others?
  • How will HIV treatment affect my lifestyle?
  • How should I tell my partner that I have HIV?
  • Is there any reason to tell my employer and those I work with that I have HIV?
  • Are there support groups for people with HIV?
  • Are there resources available to help me pay for my HIV medicines?

Remember that your health care provider wants to help make sure you have the resources you need to manage your new HIV diagnosis, so do not hesitate to ask questions.

Where can someone find resources for a person just diagnosed with HIV?

The following are resources to share with someone with newly diagnosed HIV:

  • How to Find HIV Treatment Services: An HIVinfo fact sheet listing HIV-related resources, including resources to help find a health care provider and get help paying for HIV medicines.
  • Available Care and Services: A webpage from the Ryan White HIV/AIDS Program outlining the services available for people with HIV who are low-income and have inadequate health insurance.
  • Living With HIV: A webpage from the Centers for Disease Control and Prevention (CDC) with information on living with an HIV diagnosis, including recommendations on how to share an HIV diagnosis with others.

This fact sheet is based on information from these sources: 

From the NIH Office of AIDS Research:

From the Department of Veterans Affairs:

Also see the HIV Source collection of HIV links and resources.

Long-Acting HIV Medicine

Key Points

  • Long-acting HIV medicines have become increasingly popular in recent years, offering a safe way to reduce how often medication needs to be taken.
  • Long-acting HIV medicines are injected under the supervision of a health care provider rather than consumed as a pill at home.
  • Unlike most oral HIV medicines that are taken daily, long-acting HIV medicines are injected on schedules ranging from every two weeks to every six months, depending on the medicine.

 

What are long-acting HIV medicines?

Long-acting HIV medicines are HIV medicines that stay in the body for a longer period of time. Since long-acting HIV medicines stay in the body longer, they can be taken less frequently.

Some of the most common long-acting HIV medicines include—

As of 2025, these are the only FDA-approved long-acting medicines for HIV treatment or prevention. This fact sheet will focus on HIV treatment. To learn more about HIV prevention, view the Pre-Exposure Prophylaxis fact sheet.

How are long-acting HIV medicines different?

Long-acting HIV medicines are unique because they can maintain stable concentrations in the body for much longer than most oral HIV medicines. As a result, this means that people who use long-acting HIV medicines don’t have to take pills for each HIV medicine in their treatment regimen every day.

Instead of taking pills every day, long-acting HIV medicines are injected much less frequently. For example, the FDA-approved long-acting HIV medicines are usually taken on the following schedule—

  • Cabenuva – Every one or two months
  • Sunlenca – Every six months
  • Trogarzo – Every two weeks

However, unlike HIV medicines in pill form, long-acting HIV medicines must be given at an appointment with a health care provider. Some research shows that long-acting HIV medicines could help people who struggle to take pills frequently, known as medication adherence.

Medication adherence is critical to how effective HIV medicines are. Because long-acting HIV medicines can help overcome some barriers related to adherence, many additional long-acting medicines are currently being investigated for both treatment and prevention of HIV. The HIV Treatment Adherence fact sheet provides more information on factors that impact adherence.

Although long-acting HIV medicines can be taken less frequently, sometimes other HIV medicines must still be taken every day. For instance, Sunlenca is only taken every six months, but is used to supplement other HIV medicines in your treatment regimen.

Are long-acting HIV medicines safe?

Like most other FDA-approved HIV medicines, long-acting HIV medicines are considered safe. All medicines have the potential for some side effects. For long-acting HIV medicines, the most common side effects include—

  • Diarrhea
  • Dizziness
  • Fatigue
  • Fever
  • Headache
  • Nausea
  • Rash
  • Sleep problems
  • Soreness, swelling, or redness around the injection site

Less commonly, long-acting HIV medicines can cause more serious side effects like depression or liver problems. However, serious side effects are rare and can usually be avoided by communicating with your health care provider before taking a new HIV medicine.

In addition, many HIV medicines (including long-acting HIV medicines) may be prone to drug interactions if combined with other drugs, including over-the-counter drugs. For example, long-acting HIV medicines may interact with some antibiotics and anticonvulsants.

Lastly, there is not enough data to guarantee that these medicines are safe to use during pregnancy or while breastfeeding. Although it is possible that these medicines are safe in these scenarios, they are not recommended in such cases due to a lack of data. A health care provider should help select HIV medicines based on your unique personal situation.

Should I switch to a long-acting HIV medicine?

Switching HIV medicines should only occur after consultation with a health care provider. In some cases, there will be no need to switch an HIV treatment regimen if it is working effectively and you can tolerate the current dosing schedule. Switching HIV treatment regimens may lead to drug resistance, which could limit treatment options in the future.

In addition, long-acting HIV medicines have few options, with some options reserved for unique health scenarios. For instance, Trogarzo is typically used when a person is resistant to multiple classes of HIV medicines. When this happens, normal HIV medicines do not work effectively, and Trogarzo is used somewhat like an emergency medicine.

However, there are some cases when switching to a long-acting HIV medicine is beneficial. For instance, if you are struggling to keep up with the demands of taking pills every day, long-acting HIV medicines could be more effective.

In addition, other factors that could affect your ability to take long-acting HIV medicines should be addressed. For instance, these medicines may have different costs or side effects that might not meet your needs or preferences.

If you believe you are a good candidate for a long-acting HIV medicine, it is possible that you could be eligible to use investigational long-acting HIV medicines in a clinical trial. Always consult with your health care provider about taking any new medicines and any concerns related to an HIV treatment regimen.


This fact sheet is based on information from the following sources:

From the U.S. Department of Health and Human Services:

From CDC:

From the World Health Organization:

Also see the HIV Source collection of HIV links and resources.

What is a Drug Interaction?

Key Points

  • drug interaction is a reaction between two (or more) drugs or between a drug and a food, beverage, or supplement. Certain medical conditions can also cause a drug interaction.
  • A drug interaction can affect how a drug works or cause unwanted side effects.
  • Although treatment with HIV medicines can help people with HIV live long, healthy lives and reduce the risk of HIV transmission, drug interactions can complicate HIV treatment.
  • Health care providers carefully consider potential drug interactions before recommending an HIV treatment regimen. Before taking HIV medicines, tell your health care provider about all prescription and nonprescription medicines, vitamins, nutritional supplements, and herbal products you are taking or plan to take.

 

What is a drug interaction?

Medicines help us feel better and stay healthy. However, sometimes drug interactions can cause problems. Drug interactions refer to reactions that affect how a drug acts in the body, which may change how effective or safe a drug is. There are three types of drug interactions:

  • Drug–drug interaction: A reaction between two (or more) drugs, including both prescription and over-the-counter drugs.
  • Drug–food interaction: A reaction between a drug and a food, beverage, or dietary supplement.
  • Drug–condition interaction: A reaction that occurs when taking a drug while having a certain medical condition. For example, if you have high blood pressure, taking a nasal decongestant may increase your risk of stroke or heart attack.

A drug interaction can affect drug activity levels or cause adverse events. People with HIV should be aware of potential drug interactions to make sure their HIV medicines work safely and effectively.

Flowchart image showing the key types of drug interactions and the potential effects of such interactions.

Do HIV medicines ever cause drug interactions?

Treatment with HIV medicines (called antiretroviral therapy or ART) helps people with HIV live long, healthy lives and reduces the risk of HIV transmission. However, drug interactions, especially drug–drug interactions, can complicate HIV treatment.

Drug–drug interactions commonly occur between different HIV medicines and between HIV medicines and other medicines. Before recommending an HIV treatment regimen, health care providers carefully consider potential drug–drug interactions between HIV medicines.

In addition, health care providers should also ask about other medicines a person may be taking. For example, some HIV medicines may make hormonal birth control less effective, so women using hormonal contraceptives may need to use an additional or different method of birth control to prevent pregnancy.

For more information about using birth control and HIV medicines at the same time, view the HIV and Birth Control infographic from HIVinfo.

While rare, some drug interactions can have more serious side effects. For example, some interactions can reduce kidney function, damage the liver, or cause changes to your heartbeat. These interactions can be prevented by talking to your health care provider about any medicines and supplements you take or plan to take.

Can drug-food interactions and drug-condition interactions affect people taking HIV medicines?

Yes, the use of HIV medicines can lead to both drug–food interactions and drug–condition interactions.

Both the amount and type of food (or supplement) can affect the absorption of some HIV medicines and increase or reduce the concentration of the medicine in the blood. Depending on the HIV medicine, the change in concentration may be helpful or harmful.

Some HIV medicines (such as rilpivirine) should be taken with food, while others (such as efavirenz) should be taken on an empty stomach. In addition, supplements with iron, calcium, and magnesium can affect some medicines in the integrase strand transfer inhibitor drug class.

Directions on how to take HIV medicines specify whether to take the medicine with food or on an empty stomach. Some HIV medicines (such as dolutegravir) can be taken with or without food because food does not affect their absorption.

Conditions, such as kidney disease, hepatitis, and pregnancy, can affect how the body processes HIV medicines. The dosing of some HIV medicines may need to be adjusted in people with certain medical conditions.

How can a person avoid drug interactions?

You can take the following steps to avoid drug interactions:

  • Tell your health care provider about all prescription and nonprescription medicines you are taking or plan to take. Also tell your health care provider about any vitamins, nutritional supplements, and herbal products you take.
  • Tell your health care provider about any other conditions you may have, such as high blood pressure or diabetes.
  • Before taking a medicine, ask your health care provider or pharmacist the following questions:
    • What is the medicine used for?
    • How should I take the medicine?
    • While taking the medicine, should I avoid any other medicines or certain foods or beverages?
    • Can I take this medicine safely with the other medicines that I am taking? Are there any possible drug interactions I should know about? What are the signs of those drug interactions?
    • In the case of a drug interaction, what should I do?
  • Take medicines according to your health care provider's instructions. Always read the information and directions that come with an HIV medicine. Drug labels and package inserts include important information about possible drug interactions.

If you believe you are experiencing a drug interaction of any type, be sure to contact your health care provider. Never stop taking an HIV medicine without talking to your health care provider.


This fact sheet is based on information from the following sources:

From the HIV Clinical Practice Guidelines at Clinicalinfo.HIV.gov:

From the U.S. Food and Drug Administration:

From the National Institute on Aging:

Also see the HIV Source collection of HIV links and resources.

What to Start: Choosing an HIV Treatment Regimen

Key Points

  • People with HIV take a combination of HIV medicines to form a complete HIV treatment regimen).
  • The U.S. Food and Drug Administration (FDA) has approved more than 50 HIV medicines to treat HIV infection.
  • People with HIV should discuss HIV treatment options with their health care provider to suit their individual needs, including considerations like cost, convenience, potential drug interactions, and side effects.

 

What is an HIV treatment regimen?

An HIV treatment regimen is a combination of HIV medicines used to treat HIV infection. HIV treatment (also called antiretroviral therapy or ART) begins with choosing a regimen. People on ART should take the HIV medicines in their HIV regimens exactly as prescribed, which is usually daily for pills and every one or two months for injections. ART helps people with HIV live long, healthy lives and reduces the risk of HIV transmission.

More than 50 HIV medicines are currently U.S. Food and Drug Administration (FDA)-approved to treat HIV infection. HIV medicines come in different forms, including:

  • Single-tablet regimens: Multiple HIV medicines combined into one pill or tablet
  • Multiple-tablet regimens: Multiple HIV medicines taken as two or more pills or tablets
  • Co-packaged products: Two or more HIV medicines taken separately but packaged together
  • Oral suspensions: One or more HIV medicines that are consumed in liquid form
  • Injectables: One or more HIV medicines that are injected instead of consumed

The various HIV medicines are grouped into eight drug classes based on how they fight HIV.

What are the HIV drug classes?

The eight HIV drug classes are:

Treatment regimens typically include HIV medicines from two or more drug classes. The choice of HIV medicines to include in a treatment regimen depends on a person’s individual needs, including previous treatment history.

Click here to see the HIVinfo fact sheet that lists the FDA-approved HIV medicines by drug class.

What factors are considered when choosing an HIV treatment regimen?

When choosing an HIV treatment regimen, people with HIV and their health care providers consider the following factors:

  • Other diseases or conditions that the person with HIV may have, such as heart disease
  • Possible side effects of HIV medicines
  • Potential interactions between HIV medicines or between HIV medicines and other medicines the person with HIV is taking
  • Results of drug-resistance testing (and other tests). To learn more, read the HIVinfo Drug Resistance fact sheet.
  • Convenience of the treatment regimen. For example, a single-tablet regimen may be more convenient than a multiple-tablet regimen.
  • Any issues that prevent good HIV treatment adherence. For example, a lack of health insurance or an inability to pay for HIV medicines can make it hard to take HIV medicines consistently.

The best HIV treatment regimen for a person depends on their individual needs. Some treatment regimens are considered safe and effective for most people with HIV, such as the single-tablet regimen of bictegravir, tenofovir alafenamide, and emtricitabine. In other cases, such as suspected drug resistance, a drug like bictegravir may need to be avoided.

How long does it take for HIV medicines to work?

Viral load is the amount of HIV in a person’s blood. One of the main goals of HIV treatment is to reduce a person’s viral load to an undetectable level. An undetectable viral load means that the level of HIV in the blood is too low to be detected by a viral load test.

Once HIV treatment is started, it usually takes 3 to 6 months for a person’s viral load to reach an undetectable level. Although HIV medicines cannot cure HIV, having an undetectable viral load shows that the medicines are controlling a person’s HIV. Maintaining an undetectable viral load helps people with HIV live long, healthy lives while nearly eliminating the risk of HIV transmission through sex.


This fact sheet is based on information from the following sources:

From the NIH Office of AIDS Research:

From the Department of Veterans Affairs:

Also see the HIV Source collection of HIV links and resources.

When to Start HIV Medicines

Key Points

  • Treatment with HIV medicines is recommended for everyone with HIV. HIV medicines help people with HIV live long, healthy lives and reduce the risk of HIV transmission.
  • People with HIV should start taking HIV medicines as soon as possible after an HIV diagnosis, especially pregnant women or people who have early HIV infection or AIDS-defining conditions.
  • Before starting HIV treatment, people with HIV should discuss the importance of medication adherence with their health care provider.

 

When is it time to start taking HIV medicines?

Treatment with HIV medicines (called antiretroviral therapy or ART) is recommended for everyone with HIV and should be started as soon as possible after HIV is diagnosed.

One of the main goals of HIV treatment is to reduce a person’s viral load to an undetectable level. An undetectable viral load means that the level of HIV in the blood is too low to be detected by a viral load test.

Maintaining an undetectable viral load helps a person with HIV live a long, healthy life. People with HIV who maintain an undetectable viral load have a very low risk of transmitting HIV to a partner without HIV through sex.

To reduce their viral load, it is important for people with HIV to start taking HIV medicines as soon as possible. Starting HIV medicines right away is especially important for people with HIV who have certain conditions.

What conditions make it especially important to start HIV medicines right away?

Although everyone with HIV should take HIV medicines as soon as possible, the following scenarios make it especially important:

  • Pregnancy
  • Early HIV infection
  • AIDS-defining conditions

Pregnancy

All pregnant women with HIV should take HIV medicines to protect their health and prevent perinatal transmission of HIV. Women with HIV who become pregnant and are not already taking HIV medicines should start taking HIV medicines as soon as possible and throughout pregnancy. Women who are already taking an effective HIV treatment regimen when they become pregnant can typically continue using the same regimen throughout pregnancy.

The risk of perinatal transmission of HIV during pregnancy and childbirth is lowest in those with an undetectable viral load. Maintaining an undetectable viral load also helps keep the mother-to-be healthy.

Early HIV Infection

Early HIV infection, also known as acute HIV infection, is the period up to 6 months after infection with HIV. During early HIV infection, a person’s viral load is often very high.

Studies suggest that even at this early stage of HIV infection, HIV medicines can begin to protect a person’s health. In addition, starting HIV medicines during early HIV infection significantly reduces the risk of HIV transmission.

AIDS-Defining Conditions

AIDS-defining conditions are certain infections and cancers that can be life-threatening in people with HIV. Having an AIDS-defining condition indicates that a person has the immune function of a person with acquired immunodeficiency syndrome (AIDS); promptly starting HIV medicines can improve immune function, reducing the risk of other serious infections.

Once a person starts taking HIV medicines, why is medication adherence important? 

Before starting HIV treatment, it is important to talk to your health care provider about any issues that can make sticking to an HIV treatment regimen exactly as prescribed (known as treatment adherence) difficult. For example, a busy schedule or lack of health insurance can make it hard to take HIV medicines consistently. Health care providers can recommend resources to help people deal with any issues that may interfere with adherence.

After starting an HIV treatment regimen, it’s important to maintain good medication adherence. Medication adherence is key to maintaining an undetectable viral load, which protects the immune system and reduces the risk of HIV transmission. Even missing occasional treatment doses can reduce the effectiveness of HIV medicines or lead to drug resistance.

Read the following HIVinfo fact sheets to learn more about medication adherence:


This fact sheet is based on information from the following sources: 

From the NIH Office of AIDS Research:

Also see the HIV Source collection of HIV links and resources.